<div class="qMYqUG_convSearchResultHighlightRoot">
<div class="" data-turn-id-container="request-6a17e629-f738-8321-b0bd-a7f40ee1f23a-84" data-is-intersecting="true">
<section class="text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-6a17e629-f738-8321-b0bd-a7f40ee1f23a-84" data-turn-id-container="request-6a17e629-f738-8321-b0bd-a7f40ee1f23a-84" data-testid="conversation-turn-172" data-scroll-anchor="false" data-turn="assistant">
<div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)">
<div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="0a087d86-5b0a-4e3a-8ddd-716b1a3249f0" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<p data-start="97" data-end="639">Psychosis associated with Parkinson&rsquo;s disease and Alzheimer&rsquo;s disease represents a complex neuropsychiatric complication that significantly impacts patient quality of life and increases caregiver burden. It commonly manifests as hallucinations, delusions, agitation, and distorted perception of reality. In Parkinson&rsquo;s disease, psychotic symptoms are often linked to dopaminergic therapy and disease progression, whereas in Alzheimer&rsquo;s disease, they are primarily driven by neurodegenerative changes affecting memory, cognition, and behavior.</p>
<p data-start="641" data-end="1138">The market for psychosis in neurodegenerative disorders is witnessing gradual expansion due to rising disease prevalence, aging populations, and increased awareness of neuropsychiatric symptoms. The growing diagnosis rate of Parkinson&rsquo;s and Alzheimer&rsquo;s diseases globally is contributing to an expanding patient pool requiring effective symptom management. However, treatment remains challenging due to the delicate balance between controlling psychosis and preserving cognitive and motor function.</p>
<p data-start="1140" data-end="1644">Currently, therapeutic strategies include atypical antipsychotics, cholinesterase inhibitors, and dose adjustments of dopaminergic medications in Parkinson&rsquo;s patients. Pimavanserin has emerged as a notable treatment option specifically approved for Parkinson&rsquo;s disease psychosis, offering efficacy with minimal motor side effects. In Alzheimer&rsquo;s-related psychosis, treatment remains largely off-label, with ongoing reliance on antipsychotics used cautiously due to safety concerns in elderly populations.</p>
<p data-start="1646" data-end="2054">The pipeline for psychosis in neurodegenerative diseases is evolving, with pharmaceutical companies exploring serotonin receptor modulators, neuroinflammation-targeting agents, and novel CNS-acting compounds aimed at improving efficacy and safety profiles. Non-pharmacological interventions, including behavioral therapy and caregiver support, also play an important role in comprehensive disease management.</p>
<p data-start="2056" data-end="2328" data-is-last-node="" data-is-only-node="">Overall, the psychosis in <strong><a href="https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market">Parkinson&rsquo;s and Alzheimer&rsquo;s disease Market</a></strong> is expected to grow steadily, driven by unmet clinical needs, advancements in neuropsychiatric drug development, and increasing focus on improving patient-centric outcomes in neurodegenerative disorders.</p>
</div>
</div>
</div>
</div>
<div class="z-0 flex min-h-[46px] justify-start">&nbsp;</div>
<div class="mt-3 w-full empty:hidden">&nbsp;</div>
</div>
</div>
</section>
</div>
</div>
<div class="pointer-events-none -mt-px h-px translate-y-[calc(var(--scroll-root-safe-area-inset-bottom)-14*var(--spacing))]" aria-hidden="true">&nbsp;</div>

Psychosis in Parkinson’s and Alzheimer’s Disease Market

Psychosis in Parkinson’s and Alzheimer’s Disease Infographics

Psychosis in Parkinson’s and Alzheimer’s Disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape